Annovis Bio

Historical price data

Annovis Bio is a neuroscience-focused biotech founded in 2008 with a mission to halt nerve cell death in neurodegenerative disorders. Its core technology centers on buntanetap, a small molecule that inhibits the production of neurotoxic proteins like amyloid-beta, tau, and alpha-synuclein, aiming to restore axonal transport and synaptic function. The company is advancing late-stage clinical programs for Alzheimer's and Parkinson's disease, positioning itself as a potential next-generation treatment option in a challenging therapeutic area with high unmet need.

Buntanetap is a small molecule oral translational inhibitor designed to bind to mRNA of multiple neurotoxic proteins (amyloid-beta, tau, alpha-synuclein), reducing their production to restore axonal transport and synaptic function.

Competes against large pharma monoclonal antibodies (e.g., Biogen/Eisai's Leqembi) in Alzheimer's. Differentiation lies in buntanetap's oral, small-molecule, multi-target approach aimed at upstream protein production, versus downstream clearance of single proteins.